AU2002348178A1 - Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome - Google Patents

Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome Download PDF

Info

Publication number
AU2002348178A1
AU2002348178A1 AU2002348178A AU2002348178A AU2002348178A1 AU 2002348178 A1 AU2002348178 A1 AU 2002348178A1 AU 2002348178 A AU2002348178 A AU 2002348178A AU 2002348178 A AU2002348178 A AU 2002348178A AU 2002348178 A1 AU2002348178 A1 AU 2002348178A1
Authority
AU
Australia
Prior art keywords
amount
daunorubicin
days
cytarabine
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002348178A
Other languages
English (en)
Inventor
Mark Stanley Berger
Jay Marshall Feingold
Lance Howard Leopold
Matthew Leigh Sherman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of AU2002348178A1 publication Critical patent/AU2002348178A1/en
Priority to AU2010201113A priority Critical patent/AU2010201113A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • E—FIXED CONSTRUCTIONS
    • E05—LOCKS; KEYS; WINDOW OR DOOR FITTINGS; SAFES
    • E05F—DEVICES FOR MOVING WINGS INTO OPEN OR CLOSED POSITION; CHECKS FOR WINGS; WING FITTINGS NOT OTHERWISE PROVIDED FOR, CONCERNED WITH THE FUNCTIONING OF THE WING
    • E05F3/00—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices
    • E05F3/04—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes
    • E05F3/10—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes with a spring, other than a torsion spring, and a piston, the axes of which are the same or lie in the same direction
    • E05F3/108—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes with a spring, other than a torsion spring, and a piston, the axes of which are the same or lie in the same direction with piston rod protruding from the closer housing; Telescoping closers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • E—FIXED CONSTRUCTIONS
    • E05—LOCKS; KEYS; WINDOW OR DOOR FITTINGS; SAFES
    • E05F—DEVICES FOR MOVING WINGS INTO OPEN OR CLOSED POSITION; CHECKS FOR WINGS; WING FITTINGS NOT OTHERWISE PROVIDED FOR, CONCERNED WITH THE FUNCTIONING OF THE WING
    • E05F3/00—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002348178A 2002-11-06 2002-11-06 Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome Abandoned AU2002348178A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2010201113A AU2010201113A1 (en) 2002-11-06 2010-03-22 Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/035532 WO2004043461A1 (en) 2002-11-06 2002-11-06 Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2010201113A Division AU2010201113A1 (en) 2002-11-06 2010-03-22 Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome

Publications (1)

Publication Number Publication Date
AU2002348178A1 true AU2002348178A1 (en) 2004-06-03

Family

ID=32311637

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2002348178A Abandoned AU2002348178A1 (en) 2002-11-06 2002-11-06 Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
AU2010201113A Abandoned AU2010201113A1 (en) 2002-11-06 2010-03-22 Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2010201113A Abandoned AU2010201113A1 (en) 2002-11-06 2010-03-22 Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome

Country Status (10)

Country Link
EP (1) EP1575582A4 (pt)
JP (1) JP2006508119A (pt)
CN (1) CN1720044A (pt)
AU (2) AU2002348178A1 (pt)
BR (1) BR0215935A (pt)
CA (1) CA2504611A1 (pt)
CR (1) CR7804A (pt)
MX (1) MXPA05004711A (pt)
NO (1) NO20052009L (pt)
WO (1) WO2004043461A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006050075A2 (en) * 2004-10-29 2006-05-11 Regents Of The University Of California Method of increasing efficacy of tumor cell killing using combinations of anti-neoplastic agents
EP1661584A1 (en) * 2004-11-26 2006-05-31 Heinz Dr. Faulstich Use of conjugates of amatoxins and phallotoxins with macromolecules for cancer and inflammation therapy
AU2006269481A1 (en) * 2005-07-06 2007-01-18 Kanisa Pharmaceuticals, Inc. Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar
ES2371085T3 (es) * 2006-05-27 2011-12-27 Faulstich, Heinz, Dr. Utilización de conjugados de amatoxinas o falotoxinas con macromoléculas para la terapia tumoral y de la inflamación.
CN1994293A (zh) * 2006-08-18 2007-07-11 上海交通大学医学院附属瑞金医院 冬凌草甲素在制药中的应用
AU2007317333A1 (en) * 2006-11-02 2008-05-15 Seattle Genetics, Inc. Methods of treating neoplastic, autoimmune and inflammatory diseases
HRP20220428T3 (hr) * 2007-02-16 2022-05-27 Rotalec Ip Holdings Llc Fiksni omjeri lijeka za liječenje hematopoetskih tumora i proliferativnih poremećaja
WO2009075841A2 (en) * 2007-12-10 2009-06-18 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
EP2333108A4 (en) 2008-08-29 2012-05-09 School Juridical Person The Kitasato Inst METHOD FOR DETERMINING THE HEALING EFFECT OF DNA METHYLATION INHIBITORS
US12071450B2 (en) 2015-12-03 2024-08-27 Biosight Ltd. Salts of conjugates for cancer therapy
US12064445B2 (en) 2015-12-03 2024-08-20 Biosight Ltd. Cytarabine conjugates for cancer therapy
EP3442584B1 (en) 2016-03-15 2021-07-28 Seagen Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
EP3463463A4 (en) * 2016-06-03 2020-01-15 Seattle Genetics, Inc. COMBINATION OF CD33 ANTIBODY-ACTIVE SUBSTANCE CONJUGATES WITH CHEMOTHERAPEUTICS
US11191771B2 (en) 2016-06-09 2021-12-07 Seagen Inc. Combinations of PBD-based antibody drug conjugates with FLT3 inhibitors
BR112019026959A2 (pt) * 2017-06-22 2020-07-07 Les Laboratoires Servier combinação de um inibidor de mcl-1 e um tratamento com padrão de atendimento para cânceres hematológicos, seus usos e composições farmacêuticas
CA3069558A1 (en) * 2017-07-09 2019-01-17 Biosight Ltd. Combination cancer therapy
CN113631193A (zh) * 2019-01-28 2021-11-09 德州大学系统董事会 用于治疗癌症的金属螯合剂组合疗法
CN110123825B (zh) * 2019-05-28 2021-11-30 宁波市鄞州人民医院 一种包含去甲氧柔红霉素的药物组合物
US20240000846A1 (en) * 2020-10-27 2024-01-04 Vor Biopharma Inc. Compositions and methods for treating hematopoietic malignancy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US20020103141A1 (en) * 1998-12-23 2002-08-01 Mckearn John P. Antiangiogenic combination therapy for the treatment of cancer
JP3888971B2 (ja) * 2000-08-08 2007-03-07 イムノメディクス， インコーポレイテッド 慢性骨髄性白血病の免疫療法

Also Published As

Publication number Publication date
CR7804A (es) 2008-10-29
NO20052009D0 (no) 2005-04-25
CA2504611A1 (en) 2004-05-27
JP2006508119A (ja) 2006-03-09
EP1575582A4 (en) 2009-03-11
NO20052009L (no) 2005-06-27
CN1720044A (zh) 2006-01-11
AU2010201113A1 (en) 2010-04-15
MXPA05004711A (es) 2005-08-03
EP1575582A1 (en) 2005-09-21
WO2004043461A1 (en) 2004-05-27
BR0215935A (pt) 2005-08-09

Similar Documents

Publication Publication Date Title
US7727968B2 (en) Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
AU2010201113A1 (en) Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
AU773506B2 (en) Antitumour synergistic composition
Seiter Toxicity of the topoisomerase II inhibitors
CN110869029A (zh) 组合癌症治疗
Herman et al. Biological properties of ICRF-159 and related bis (dioxopiperazine) compounds
Castleberry et al. The cytosine arabinoside (Ara‐C) syndrome
Arlin et al. Phase I-II Trial of Mitoxantrone in Acute Leukemia¹, 2
EP1977753A1 (en) Combined preparation comprising anthracycline derivatives
CZ20003493A3 (cs) Protinádorová kompozice obsahující synergicky působící kombinaci derivátu anthracyklinu s derivátem kamptotecinu
Chisesi et al. A phase II study of idarubicin (4-demethoxydaunorubicin) in advanced myeloma
Case Jr et al. Phase I–II trial of high-dose Epirubicin in patients with lymphoma
RU2338535C2 (ru) Комбинированная терапия для лечения острого лейкоза и миелодиспластического синдрома
Frenette et al. Granulocyte‐macrophage colony stimulating factor (GM‐CSF) priming in the treatment of elderly patients with acute myelogenous leukemia
Case Jr et al. Phase II study of aclarubicin in acute myeloblastic leukemia
CN101259129A (zh) 急性白血病和骨髓异常增生综合征的组合治疗
Reiser et al. DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide): an effective and well-tolerated new regimen for patients with relapsed lymphoma
Thomas et al. Dose-escalation study of single dose mitoxantrone in combination with timed sequential chemotherapy in patients with refractory or relapsing acute myelogenous leukemia
Greenberg et al. Treatment of myelodysplastic syndromes with daily oral idarubicin. A phase I–II study
Parikh et al. High-dose cytosine arabinoside plus etoposide as initial treatment for acute myeloid leukaemia: a single centre study
Saşmaz et al. The results of treatment with idarubicin in childhood acute nonlymphoblastic leukemia
WO1993021938A1 (en) Methods for treating cancer using high-dose epirubicin
Giles et al. Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia
Horikoshi et al. The value of oral cytarabine ocfosfate and etoposide in the treatment of refractory and elderly AML patients
Thomas et al. Intensive chemotherapy with mitoxantrone administered as a single injection in patients with high-risk acute myeloid leukemia: results of the EMA 2000 trial

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAMES OF THE CO-INVENTORS TO INCLUDE BERGER, MARK STANLEY; SHERMAN, MATTHEW LEIGH AND LEOPOLD, LANCE HOWARD

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted